blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3284754

EP3284754 - ANTI-CD38 ANTIBODIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.09.2021
Database last updated on 16.05.2026
FormerThe patent has been granted
Status updated on  02.10.2020
FormerGrant of patent is intended
Status updated on  24.05.2020
FormerExamination is in progress
Status updated on  23.11.2018
FormerRequest for examination was made
Status updated on  24.08.2018
FormerThe application has been published
Status updated on  19.01.2018
Most recent event   Tooltip03.10.2024Change - lapse in a contracting state
State(s) deleted from list of lapses: AL		published on 06.11.2024  [2024/45]
Applicant(s)For all designated states
Takeda Pharmaceutical Company Limited
1-1 Doshomachi 4-chome Chuo-ku
Osaka-shi, Osaka 541-0045 / JP
[2018/08]
Inventor(s)01 / ELIAS, Kathleen Ann
c/o Takeda California, Inc.
9625 Towne Centre Drive
San Diego, CA 92121 / US
02 / LANDES, Gregory
c/o Takeda California, Inc.
9625 Towne Centre Drive
San Diego, CA 92121 / US
03 / SINGH, Shweta
c/o Takeda California, Inc.
9625 Towne Centre Drive
San Diego, CA 92121 / US
04 / KORVER, Wouter
c/o Takeda California, Inc.
9625 Towne Centre Drive
San Diego, CA 92121 / US
05 / DRAKE, Andrew Walling
c/o Takeda California, Inc.
9625 Towne Centre Drive
San Diego, CA 92121 / US
06 / HAAK-FRENDSCHO, Mary
c/o Takeda California, Inc.
9625 Towne Centre Drive
San Diego, CA 92121 / US
07 / SNELL, Gyorgy Pal
c/o Takeda California, Inc.
9625 Towne Centre Drive
San Diego, CA 92121 / US
08 / BHASKAR, Vinay
c/o Takeda California, Inc.
9625 Towne Centre Drive
San Diego, CA 92121 / US
 [2020/45]
Former [2018/12]01 / ELIAS, Kathleen Ann
c/o Takeda California, Inc.
10410 Science Center Drive
San Diego, CA 92121 / US
02 / LANDES, Gregory
c/o Takeda California, Inc.
10410 Science Center Drive
San Diego, CA 92121 / US
03 / SINGH, Shweta
c/o Takeda California, Inc.
10410 Science Center Drive
San Diego, CA 92121 / US
04 / KORVER, Wouter
c/o Takeda California, Inc.
10410 Science Center Drive
San Diego, CA 92121 / US
05 / DRAKE, Andrew Walling
c/o Takeda California, Inc.
10410 Science Center Drive
San Diego, CA 92121 / US
06 / HAAK-FRENDSCHO, Mary
c/o Takeda California, Inc.
10410 Science Center Drive
San Diego, CA 92121 / US
07 / SNELL, Gyorgy Pal
c/o Takeda California, Inc.
10410 Science Center Drive
San Diego, CA 92121 / US
08 / BHASKAR, Vinay
c/o Takeda California, Inc.
10410 Science Center Drive
San Diego, CA 92121 / US
Former [2018/11]01 / ELIAS, Kathleen Ann
c/o Takeda San Francisco Inc.
285 East Grand Avenue
South San Francisco, CA 94080 / US
02 / LANDES, Gregory
c/o Takeda California, Inc.
10410 Science Center Drive
San Diego, CA 92121 / US
03 / SINGH, Shweta
c/o Takeda California, Inc.
10410 Science Center Drive
San Diego, CA 92121 / US
04 / KORVER, Wouter
c/o Takeda San Francisco Inc.
285 East Grand Avenue
South San Francisco, CA 94080 / US
05 / DRAKE, Andrew Walling
c/o Takeda San Francisco Inc.
285 East Grand Avenue
South San Francisco, CA 94080 / US
06 / HAAK-FRENDSCHO, Mary
c/o Takeda California, Inc.
10410 Science Center Drive
San Diego, CA 92121 / US
07 / SNELL, Gyorgy Pal
c/o Takeda California, Inc.
10410 Science Center Drive
San Diego, CA 92121 / US
08 / BHASKAR, Vinay
c/o Takeda San Francisco Inc.
285 East Grand Avenue
South San Francisco, CA 94080 / US
Former [2018/08]01 / ELIAS, Kathleen Ann
c/o Takeda San Francisco Inc.
285 East Grand Avenue
South San Francisco, CA 94080 / US
02 / LANDES, Gregory
c/o Takeda San Francisco Inc.
285 East Grand Avenue
South San Francisco, CA 94080 / US
03 / SINGH, Shweta
c/o Takeda San Francisco Inc.
285 East Grand Avenue
South San Francisco, CA 94080 / US
04 / KORVER, Wouter
c/o Takeda San Francisco Inc.
285 East Grand Avenue
South San Francisco, CA 94080 / US
05 / DRAKE, Andrew Walling
c/o Takeda San Francisco Inc.
285 East Grand Avenue
South San Francisco, CA 94080 / US
06 / HAAK-FRENDSCHO, Mary
c/o Takeda San Francisco Inc.
285 East Grand Avenue
South San Francisco, CA 94080 / US
07 / SNELL, Gyorgy Pal
c/o Takeda San Francisco Inc.
285 East Grand Avenue
South San Francisco, CA 94080 / US
08 / BHASKAR, Vinay
c/o Takeda San Francisco Inc.
285 East Grand Avenue
South San Francisco, CA 94080 / US
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Former [2018/08]D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Application number, filing date17189925.530.12.2011
[2018/08]
Priority number, dateUS201061428699P30.12.2010         Original published format: US 201061428699 P
US201161470406P31.03.2011         Original published format: US 201161470406 P
US201161470382P31.03.2011         Original published format: US 201161470382 P
US201161485104P11.05.2011         Original published format: US 201161485104 P
[2018/08]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3284754
Date:21.02.2018
Language:EN
[2018/08]
Type: B1 Patent specification 
No.:EP3284754
Date:04.11.2020
Language:EN
[2020/45]
Search report(s)(Supplementary) European search report - dispatched on:EP23.01.2018
ClassificationIPC:C07K16/28, A61P35/02
[2018/08]
CPC:
A61P1/00 (EP); C07K16/2896 (EP,CN,KR,US); C07K16/40 (US);
A61K47/6871 (EP,US); A61P1/04 (EP); A61P19/02 (EP);
A61P29/00 (EP); A61P35/00 (EP); A61P35/02 (EP);
A61P37/00 (EP,KR); A61P37/02 (EP); A61P37/06 (EP);
A61P43/00 (EP); C12N9/99 (EP,US); A61K2039/505 (EP,KR,US);
C07K2317/24 (EP,CN,US); C07K2317/30 (US); C07K2317/33 (EP,CN,KR,US);
C07K2317/34 (EP,CN,US); C07K2317/52 (US); C07K2317/56 (EP,CN,US);
C07K2317/565 (EP,CN,US); C07K2317/732 (EP,CN,US); C07K2317/734 (EP,CN,US);
C07K2317/76 (US); C07K2317/77 (KR); C07K2317/92 (EP,CN,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/39]
Former [2018/08]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA20.08.2018
ME20.08.2018
TitleGerman:ANTI-CD38-ANTIKÖRPER[2018/08]
English:ANTI-CD38 ANTIBODIES[2018/08]
French:ANTICORPS ANTI-CD38[2018/08]
Examination procedure07.09.2017Date on which the examining division has become responsible
20.08.2018Amendment by applicant (claims and/or description)
20.08.2018Examination requested  [2018/39]
26.11.2018Despatch of a communication from the examining division (Time limit: M04)
26.03.2019Reply to a communication from the examining division
26.02.2020Cancellation of oral proceeding that was planned for 03.03.2020
03.03.2020Date of oral proceedings (cancelled)
25.05.2020Communication of intention to grant the patent
24.09.2020Fee for grant paid
24.09.2020Fee for publishing/printing paid
24.09.2020Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP11811633.4  / EP2658871
Divisional application(s)EP20198444.0  / EP3789404
Opposition(s)05.08.2021No opposition filed within time limit [2021/41]
Fees paidRenewal fee
05.10.2017Renewal fee patent year 03
05.10.2017Renewal fee patent year 04
05.10.2017Renewal fee patent year 05
05.10.2017Renewal fee patent year 06
27.12.2017Renewal fee patent year 07
31.12.2018Renewal fee patent year 08
27.12.2019Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipSM04.11.2020
[2024/45]
Former [2021/45]AL04.11.2020
SM04.11.2020
Former [2021/32]SM04.11.2020
Documents cited:Search[Y] WO2006125640  (MORPHOSYS AG et al.)
 [A] WO2006099875  (GENMAB AS et al.)
 [Y]   STEPHAN DUEBEL ED - STEFAN DBEL: "Handbook of Therapeutic Antibodies Chapter 6", 1 January 2007, HANDBOOK OF THERAPEUTIC ANTIBO, WILEY-VCH, WEINHEIM, PAGE(S) 119 - 144, ISBN: 978-3-527-31453-9, XP007913671
 [A]   PARK PETER U ET AL: "SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies.", BLOOD, vol. 112, no. 11, November 2008 (2008-11-01), & 50TH ANNUAL MEETING OF THE AMERICAN- SOCIETY-OF-HEMATOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 06 -09, 2008, pages 951, XP009157535, ISSN: 0006-4971
 [A]   KONG SUN-YOUNG ET AL: "Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs", BLOOD, vol. 116, no. 21, November 2010 (2010-11-01), & 52ND ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); ORLANDO, FL, USA; DECEMBER 04 -07, 2010, pages 1241 - 1242, XP009157536
 [A]   GROEN RICHARD W ET AL: "In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma", BLOOD, vol. 116, no. 21, November 2010 (2010-11-01), & 52ND ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); ORLANDO, FL, USA; DECEMBER 04 -07, 2010, pages 1261 - 1262, XP009157537
by applicantWO03011161
 WO9413804
 WO9211018
 US5530101
 US5585089
 US5693761
 US5693762
 US6180370
 US5859205
 US5821337
 US6054297
 US6407213
 US45900404
 US81051001
 US84165407
 US2004013210
 US2005054832
 US2006024298
 US2006121032
 US2006235208
 US2007148170
 US34176908
 US6737056
 US7670600
 US6086875
 US3969287
 US3691016
 US4195128
 US4247642
 US4229537
 US4330440
 US6602684
 US27737002
 US11392902
 WO0061739
 WO0129246
 WO0231140
 WO0230954
 WO8705330
 US4640835
 US4496689
 US4301144
 US4670417
 US4791192
 US4179337
 US2005114037
 US3773919
 US5057313
 US6331175
 US9315584
 WO2006099875
 WO2008047242
   ANTONELLI ET AL., CLIN. EXP. IMMUNOL., vol. 126, 2001, pages 426 - 431
   MALLONE ET AL., DIABETES, vol. 50, 2001, pages 752
   ANTONELLI ET AL., J. ENDOCRINOL. INVEST., vol. 27, 2004, pages 695 - 707
   KABAT ET AL.: "SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
   CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
   E.A. KABAT: "SEQUENCES OF IMMUNOLOGICAL INTEREST", NIH
   WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
   BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
   HUSTON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879 - 5883
   TOMLINSON, METHODS ENZYMOL., vol. 326, 2000, pages 461 - 479
   HOLLIGER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 6444 - 6448
   JONES, NATURE, vol. 321, 1986, pages 522 - 525
   VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
   ROQUE ET AL., BIOTECHNOL. PROG., vol. 20, 2004, pages 639 - 654
   TSURUSHITA; VASQUEZ: "Molecular Biology of B Cells", 2004, ELSEVIER SCIENCE, article "Humanization of Monoclonal Antibodies", pages: 533 - 545
   JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
   RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
   QUEEN ET AL., PROC NATL ACAD SCI, USA, vol. 86, 1989, pages 10029 - 33
   HE ET AL., J. IMMUNOL., vol. 160, 1998, pages 1029 - 1035
   CARTER ET AL., PROC NATL ACAD SCI USA, vol. 89, 1992, pages 4285 - 9
   PRESTA ET AL., CANCER RES., vol. 57, no. 20, 1997, pages 4593 - 9
   GORMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 4181 - 4185
   O'CONNOR ET AL., PROTEIN ENG, vol. 11, 1998, pages 321 - 8
   ROGUSKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 969 - 973
   WU ET AL., J. MOL. BIOL., vol. 294, 1999, pages 151 - 162
   BACA ET AL., J. BIOL. CHEM., vol. 272, no. 16, 1997, pages 10678 - 10684
   ROSOK ET AL., J. BIOL. CHEM., vol. 271, no. 37, 1996, pages 22611 - 22618
   RADER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 8910 - 8915
   KRAUSS ET AL., PROTEIN ENGINEERING, vol. 16, no. 10, 2003, pages 753 - 759
   TAN ET AL., J. IMMUNOL., vol. 169, 2002, pages 1119 - 1125
   DE PASCALIS ET AL., J. IMMUNOL., vol. 169, 2002, pages 3076 - 3084
   HOLLIGER; WINTER, CURRENT OPINION BIOTECHNOL., vol. 4, 1993, pages 446 - 449
   HU ET AL., CANCER RES., vol. 56, 1996, pages 3055 - 3061
   MARKS ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 779 - 783
   BARBAS ET AL., PROC. NAT. ACAD. SCI, USA, vol. 91, 1994, pages 3809 - 3813
   SHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155
   YELTON ET AL., J. IMMUNOL., vol. 155, 1995, pages 1994 - 2004
   JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 9
   HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896
   REITER, NATURE BIOTECH., vol. 14, 1996, pages 1239 - 1245
   T. E. CREIGHTON: "Proteins: Structure and Molecular Properties", 1983, W. H. FREEMAN & CO., pages: 79 - 86
   UMANA ET AL., NAT BIOTECHNOL, vol. 17, 1999, pages 176 - 180
   DAVIES, BIOTECHNOL BIOENG, vol. 74, 2001, pages 288 - 294
   SHIELDS ET AL., J BIOL CHEM, vol. 277, 2002, pages 26733 - 26740
   SHINKAWA ET AL., J BIOL CHEM, vol. 278, 2003, pages 3466 - 3473
   APLIN; WRISTON, CRC CRIT. REV. BIOCHEM., 1981, pages 259 - 306
   HAKIMUDDIN, ARCH. BIOCHEM. BIOPHYS., vol. 259, 1987, pages 52
   EDGE ET AL., ANAL. BIOCHEM., vol. 118, 1981, pages 131
   THOTAKURA ET AL., METH. ENZYMOL., vol. 138, 1987, pages 350
   DUSKIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 3105
   "Antibody Engineering", 2001, SPRINGER
   HAYHURST; GEORGIOU, CURR OPIN CHEM BIOL, vol. 5, 2001, pages 683 - 689
   MAYNARD; GEORGIOU, ANNU REV BIOMED ENG, vol. 2, 2000, pages 339 - 76
   MORRISON, S., SCIENCE, vol. 229, 1985, pages 1202
   JACKSON ET AL., CLIN. EXP. IMMUNOL., vol. 72, 1988, pages 351 - 356
   DIIRIG ET AL., LEUKEMIA, vol. 16, 2002, pages 30 - 5
   MORABITO ET AL., LEUKEMIA RESEARCH, vol. 25, 2001, pages 927 - 32
   MARINOV ET AL., NEOPLASMA, vol. 40, no. 6, 1993, pages 355 - 8
   JELINEK ET AL., BR. J. HAEMATOL., vol. 115, 2001, pages 854 - 61
   KEYHANI ET AL., LEUKEMIA RESEARCH, vol. 24, 1999, pages 153 - 9
   DURIG ET AL., LEUKEMIA, vol. 16, 2002, pages 30 - 5
   HAMBLIN ET AL., BLOOD, vol. 99, 2002, pages 1023 - 9
   N. ENGL. J. MED., vol. 356, no. 25, 2007, pages 2582 - 2590
   BR. J. HAEMATOL., vol. 121, 2003, pages 749 - 57
   BR. J. HAEMATOL., vol. 121, 2003, pages 631 - 636
   "Remington's Pharmaceutical Sciences", 1980
   "Radiolabeled Monoclonal Antibodies For Imaging And Therapy", 1988, PLENUM PRESS
   CHASE ET AL.: "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO., article "Medical Applications of Radioisotopes", pages: 624 - 652
   BROWN ET AL.: "Biotechnology And Pharmacy", 1993, CHAPMAN & HALL, article "Clinical Use of Monoclonal Antibodies", pages: 227 - 49
   RICHARD P. HAUGLAND: "Molecular Probes Handbook"
   MARKS ET AL., METHODS MOL. BIOL., vol. 248, 2004, pages 161 - 76
   "Methods in Molecular Biology", vol. 178, HUMANA PRESS, article "Antibody Phage Display: Methods and Protocols"
   COOMBER, D.W.J., PANNING OF ANTIBODY PHAGE-DISPLAY LIBRARIES, pages 133 - 145
   CHAMES ET AL., SELECTION OF ANTIBODIES AGAINST BIOTINYLATED ANTIGENS, pages 147 - 157
   SAM BROOK; RUSSELL: "Molecule Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
   DRAKE; KLAKAMP: "A rigorous multiple independent binding site model for determining cell-based equilibrium dissociation constants", J. IMMUNOL. METHODS, vol. 318, 2007, pages 157 - 62
   PACE ET AL.: "How to measure and predict molar absorption coefficient of a protein", PROTEIN SCIENCE, vol. 4, no. 11, 1995, pages 2411 - 23, XP001036779
   PACE; GRIMSLEY: "Current Protocols in Protein Science", 2004, article "Spectrophotometric determination of protein concentration"
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.